Tear Substance Indicates Possible Nerve Damage in Diabetes Patients
By LabMedica International staff writers Posted on 17 Jul 2017 |
Image: A space-filling model of substance P (Photo courtesy of Wikimedia Commons).
Measurement of levels of substance P peptide in tears has been proposed as a method for determining possible nerve damage in individuals suffering from diabetes.
Substance P is a neuropeptide composed of a chain of 11 amino acid residues. It is member of the tachykinin neuropeptide family and acts as a neurotransmitter and neuromodulator. Its receptor - the neurokinin type 1 - is distributed over cytoplasmic and nuclear membranes of many cell types (neurons, glia, endothelia of capillaries and lymphatics, fibroblasts, stem cells, white blood cells) in many tissues and organs.
Investigators at the University of New South Wales (Sydney, Australia) determined total protein content and substance P concentrations in tear samples obtained from 17 healthy control individuals and nine diabetes patients. Corneal nerve fiber density, an indication of diabetes-related damage to the peripheral nerves (peripheral neuropathy), was measured by confocal microscopy.
Results revealed that while there was no significant difference in total protein content between the groups, substance P concentrations were significantly higher in the tears of the control group compared to the diabetes patients. The diabetes patients also displayed significantly lower corneal nerve fiber density, indicating loss of corneal nerve fibers. Substance P levels were moderately correlated with the corneal nerve fiber density measurements.
First author Dr. Maria Markoulli, a lecturer in optometry and vision science at the University of New South Wales, said, "The positive correlation between substance P and corneal nerve density indicates that substance P may be a potential biomarker for corneal nerve health."
The study was published in the July 7, 2017, issue of the journal Optometry and Vision Science.
Related Links:
University of New South Wales
Substance P is a neuropeptide composed of a chain of 11 amino acid residues. It is member of the tachykinin neuropeptide family and acts as a neurotransmitter and neuromodulator. Its receptor - the neurokinin type 1 - is distributed over cytoplasmic and nuclear membranes of many cell types (neurons, glia, endothelia of capillaries and lymphatics, fibroblasts, stem cells, white blood cells) in many tissues and organs.
Investigators at the University of New South Wales (Sydney, Australia) determined total protein content and substance P concentrations in tear samples obtained from 17 healthy control individuals and nine diabetes patients. Corneal nerve fiber density, an indication of diabetes-related damage to the peripheral nerves (peripheral neuropathy), was measured by confocal microscopy.
Results revealed that while there was no significant difference in total protein content between the groups, substance P concentrations were significantly higher in the tears of the control group compared to the diabetes patients. The diabetes patients also displayed significantly lower corneal nerve fiber density, indicating loss of corneal nerve fibers. Substance P levels were moderately correlated with the corneal nerve fiber density measurements.
First author Dr. Maria Markoulli, a lecturer in optometry and vision science at the University of New South Wales, said, "The positive correlation between substance P and corneal nerve density indicates that substance P may be a potential biomarker for corneal nerve health."
The study was published in the July 7, 2017, issue of the journal Optometry and Vision Science.
Related Links:
University of New South Wales
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear